biOasis Announces Oversubscription of Financing
31. März 2017 18:06 ET
|
biOasis Technologies Inc.
VANCOUVER, BC--(Marketwired - March 31, 2017) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESBIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE:...
biOasis Provides AGM Update -- Expanding The biOasis Deal Flow Pipeline
22. Januar 2017 21:30 ET
|
biOasis Technologies Inc.
VANCOUVER, BC--(Marketwired - January 22, 2017) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on the delivery of therapeutic drugs...
biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured on the Cover of Pharmaceutical Research's December Journal
06. November 2016 22:00 ET
|
biOasis Technologies Inc.
VANCOUVER, BC--(Marketwired - November 06, 2016) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of...
biOasis Engages Rising Tide Equity to Increase Global Awareness
23. Oktober 2016 19:55 ET
|
biOasis Technologies Inc.
VANCOUVER, BC--(Marketwired - October 23, 2016) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of...
biOasis Enters Into a License Agreement With Vaccinex Inc.
20. September 2016 20:00 ET
|
biOasis Technologies Inc.
VANCOUVER, BC--(Marketwired - September 20, 2016) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) ("biOasis"), a pioneering biopharmaceutical company focused on overcoming the...
biOasis Announces Publication of Scientific Paper -- Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model
29. August 2016 17:47 ET
|
biOasis Technologies Inc.
VANCOUVER, BC--(Marketwired - August 29, 2016) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of...
biOasis Announces the Issuance of an Additional US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier
10. Juli 2016 20:53 ET
|
biOasis Technologies Inc.
VANCOUVER, BC--(Marketwired - July 10, 2016) - biOasis Technologies Inc. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of...
biOasis Technologies Inc. to Present at BIO International Conference in San Francisco on June 7, 2016
17. Mai 2016 18:07 ET
|
biOasis Technologies Inc.
VANCOUVER, BC--(Marketwired - May 17, 2016) -
BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of...
biOasis Technologies Enters Into a License Agreement With Astellas Research Institute of America LLC
21. April 2016 18:28 ET
|
biOasis Technologies Inc.
VANCOUVER, BC--(Marketwired - April 21, 2016) - biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company") announces that it has entered into a License Agreement to collaborate...
biOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain
17. März 2016 23:36 ET
|
biOasis Technologies Inc.
VANCOUVER, BC--(Marketwired - March 17, 2016) - biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company") on Saturday, March 19, 2016 at 11:45am, will present the data from the...